GleamWall
中文EN

IMVT Immunovant, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1764013 · Fiscal year ends 03/31

Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-9.5%
TTM EPS YoY9.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-86.5%
ROA-75.7%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets13.7%
Debt / equity0.00x
Current ratio7.31x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.78x
Accruals ratio-17.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2027Q22026-09-302027Q12026-06-302026Q4*2026-03-312026Q32025-12-312026Q22025-09-302026Q12025-06-302025Q4*2025-03-312025Q32024-12-31
Income statement
Revenue————————
R&D expense$85.01M$142.63M$142.29M$98.92M$114.25M$101.20M$93.65M$94.52M
SG&A expense$19.14M$17.69M$17.27M$15.44M$17.51M$26.02M$20.17M$19.78M
Pretax income-$97.25M-$153.22M-$150.70M-$109.08M-$125.91M-$119.70M-$105.87M-$110.97M
Income tax$0$0-$2.84M$1.55M$594,000$913,000$583,000$152,000
Net income-$97.25M-$153.22M-$147.86M-$110.64M-$126.50M-$120.61M-$106.45M-$111.12M
EPS (basic)-0.47-0.75—-0.61-0.73-0.71—-0.76
EPS (diluted)-0.47-0.75—-0.61-0.73-0.71—-0.76
Weighted avg. shares (diluted)206.67M205.55M—181.51M173.64M170.87M—146.92M
Balance sheet
Cash & equivalents$722.27M$797.80M$902.11M$994.52M$521.87M$598.91M$713.97M$374.69M
Receivables$138,000$697,000$1.13M$1.64M$1.97M$1.94M$2.08M$2.22M
Current assets$760.05M$851.18M$948.82M$1.04B$573.55M$651.76M$767.66M$412.54M
PP&E, net$262,000$351,000$443,000$531,000$632,000$737,000$844,000$752,000
Total assets$760.97M$852.49M$957.01M$1.05B$582.96M$661.44M$776.22M$420.93M
Current liabilities$104.02M$117.10M$104.42M$66.26M$63.25M$52.90M$68.78M$68.31M
Total liabilities$104.02M$117.10M$104.42M$66.26M$63.25M$52.90M$68.78M$68.31M
Shareholders' equity$656.95M$735.39M$852.59M$986.13M$519.71M$608.54M$707.45M$352.62M
Shares outstanding206.79M206.26M203.94M203.32M174.53M171.07M170.11M147.20M
Cash flow statement
Operating cash flow-$83.22M-$124.41M-$95.06M-$92.33M-$102.52M-$117.41M-$110.64M-$100.39M
Capital expenditure——$8,000$0$0$0$201,000$180,000
Free cash flow——-$95.07M-$92.33M-$102.52M-$117.41M-$110.84M-$100.57M
Investing cash flow——-$8,000$0$0$0-$201,000-$180,000
Financing cash flow$7.88M$20.10M$3.64M$564.60M$24.59M$2.92M$450.61M$2.46M
Depreciation & amortization$89,000$92,000$96,000$101,000$105,000$107,000$109,000$99,000
Stock-based compensation$12.89M$13.77M$11.14M$12.53M$13.19M$18.51M$11.69M$11.65M

Free plan shows the latest 8 periods; Pro shows all 35 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.